Biohaven Pharmaceutical H... (BHVN)
| Bid | 26.7 |
| Market Cap | 2.82B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -946.81M |
| EPS (ttm) | -9.13 |
| PE Ratio (ttm) | -3.02 |
| Forward PE | -6.48 |
| Analyst | Buy |
| Ask | 28.29 |
| Volume | 882,492 |
| Avg. Volume (20D) | 969,920 |
| Open | 28.25 |
| Previous Close | 28.39 |
| Day's Range | 26.70 - 28.44 |
| 52-Week Range | 26.57 - 55.72 |
| Beta | 3.91 |
About BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavegepant that is in phase III clinical trials for acute and preventive treatment of migraine, as well as re...
Analyst Forecast
According to 14 analyst ratings, the average rating for BHVN stock is "Buy." The 12-month stock price forecast is $61.5, which is an increase of 122.83% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago · accessnewswire.com
Shareholder Rights Advocates at Levi & Korsinsky Investigate Biohaven Ltd. (BHVN) Regarding Possible Securities Fraud ViolationsNEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.
1 week ago · accessnewswire.com
Levi & Korsinsky Reminds Biohaven Ltd. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - BHVNNEW YORK, NY / ACCESS Newswire / March 16, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.